ID HuG1-N AC CVCL_4846 SY HuG-1N; HUG1N DR CLO; CLO_0050788 DR ArrayExpress; E-MTAB-2770 DR BioSample; SAMN03472167 DR BioSample; SAMN10987865 DR cancercelllines; CVCL_4846 DR Cell_Model_Passport; SIDM01753 DR Cosmic; 1187276 DR DepMap; ACH-000239 DR GEO; GSM887145 DR GEO; GSM888217 DR IARC_TP53; 21632 DR LiGeA; CCLE_573 DR PharmacoDB; HuG1N_636_2019 DR Progenetix; CVCL_4846 DR RCB; RCB1179 DR Wikidata; Q54896838 RX PubMed=15901131; RX PubMed=22460905; RX PubMed=25984343; RX PubMed=30894373; RX PubMed=31068700; RX PubMed=31395879; RX PubMed=31978347; CC Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE). CC Part of: TCGA-110-CL cell line panel. CC Population: Japanese. CC Doubling time: 33 hours (PubMed=25984343). CC Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.His193Pro (c.578A>C); ClinVar=VCV000376612; Zygosity=Unspecified (PubMed=15901131). CC Omics: Genomics; Whole exome sequencing. CC Omics: Phenotyping; shRNA library screening. CC Omics: Proteomics; Quantitative. CC Omics: Transcriptomics; Microarray. CC Omics: Transcriptomics; RNAseq. CC Omics: Variations; SNP array analysis. CC Genome ancestry: African=1.71%; Native American=0.2%; East Asian, North=75.56%; East Asian, South=21.1%; South Asian=0%; European, North=0%; European, South=1.43% (PubMed=30894373). CC Misspelling: HuG-N; Cosmic=1187276. CC Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795. ST Source(s): RCB=RCB1179 ST Amelogenin: X ST CSF1PO: 10,11 ST D13S317: 11 ST D16S539: 9,10 ST D5S818: 10 ST D7S820: 10 ST TH01: 7 ST TPOX: 8,11 ST vWA: 16 DI NCIt; C5473; Gastric tubular adenocarcinoma OX NCBI_TaxID=9606; ! Homo sapiens (Human) HI CVCL_4845 ! HuG-1 SX Male AG 55Y CA Cancer cell line DT Created: 04-04-12; Last updated: 10-04-25; Version: 28 // RX PubMed=15901131; DOI=10.1016/j.prp.2005.01.002; RA Murai Y., Hayashi S., Takahashi H., Tsuneyama K., Takano Y.; RT "Correlation between DNA alterations and p53 and p16 protein RT expression in cancer cell lines."; RL Pathol. Res. Pract. 201:109-115(2005). // RX PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027; RA Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., RA Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., RA Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., RA Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., RA Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., RA Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., RA Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., RA Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., RA Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., RA Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., RA Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.; RT "The Cancer Cell Line Encyclopedia enables predictive modelling of RT anticancer drug sensitivity."; RL Nature 483:603-607(2012). // RX PubMed=25984343; DOI=10.1038/sdata.2014.35; PMCID=PMC4432652; RA Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S., RA East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H., RA Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M., RA Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S., RA Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D., RA Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C., RA Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P., RA Golub T.R., Root D.E., Hahn W.C.; RT "Parallel genome-scale loss of function screens in 216 cancer cell RT lines for the identification of context-specific genetic RT dependencies."; RL Sci. Data 1:140035.1-140035.12(2014). // RX PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675; RA Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.; RT "An interactive resource to probe genetic diversity and estimated RT ancestry in cancer cell lines."; RL Cancer Res. 79:1263-1273(2019). // RX PubMed=31068700; DOI=10.1038/s41586-019-1186-3; PMCID=PMC6697103; RA Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., RA McDonald E.R. 3rd, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., RA Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., RA Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., RA Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., RA Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., RA Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., RA Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., RA Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., RA Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., RA Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., RA Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., RA Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., RA Sellers W.R.; RT "Next-generation characterization of the Cancer Cell Line RT Encyclopedia."; RL Nature 569:503-508(2019). // RX PubMed=31395879; DOI=10.1038/s41467-019-11415-2; PMCID=PMC6687785; RA Yu K., Chen B., Aran D., Charalel J., Yau C., Wolf D.M., RA van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.; RT "Comprehensive transcriptomic analysis of cell lines as models of RT primary tumors across 22 tumor types."; RL Nat. Commun. 10:3574.1-3574.11(2019). // RX PubMed=31978347; DOI=10.1016/j.cell.2019.12.023; PMCID=PMC7339254; RA Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. 3rd, RA Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K., RA Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K., RA Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A., RA Sellers W.R., Gygi S.P.; RT "Quantitative proteomics of the Cancer Cell Line Encyclopedia."; RL Cell 180:387-402.e16(2020). //